EMERGING THERAPIES IN MULTIPLE SCLEROSIS

s, Platform Presentations . . . . . . . . . . . . . . . . . . . . . . . . . .15 Abstracts, Poster Presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . .19s, Poster Presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . .19

[1]  J. Stockman.  Insulin Needs After CD3-Antibody Therapy in New-Onset Type 1 Diabetes , 2007 .

[2]  Stephen G. Waxman,et al.  Axonal conduction and injury in multiple sclerosis: the role of sodium channels , 2006, Nature Reviews Neuroscience.

[3]  A. Bar-Or,et al.  Altered CD 4 / CD 8 T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis , 2006 .

[4]  H. Waldmann,et al.  Infectious tolerance and the long‐term acceptance of transplanted tissue , 2006, Immunological reviews.

[5]  S. Cepok,et al.  Immune surveillance in multiple sclerosis patients treated with natalizumab , 2006, Annals of neurology.

[6]  T. Waldmann,et al.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Scheyer,et al.  A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses , 2006, Neurology.

[8]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[9]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[10]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[11]  H. Hartung,et al.  Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. , 2005, Archives of neurology.

[12]  F. Barkhof,et al.  Treatment with laquinimod reduces development of active MRI lesions in relapsing MS , 2005, Neurology.

[13]  H. Waldmann,et al.  The window of therapeutic opportunity in multiple sclerosis , 2005, Journal of Neurology.

[14]  J. Rose,et al.  Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody , 2004, Annals of neurology.

[15]  T. Waldmann,et al.  Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  V. Durkalski,et al.  Oral simvastatin treatment in relapsing-remitting multiple sclerosis , 2004, The Lancet.

[17]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[18]  D. Kioussis,et al.  "Infectious" transplantation tolerance , 1993, Science.

[19]  H. Waldmann,et al.  Induction of tolerance by monoclonal antibody therapy , 1986, Nature.